IL229771B - Peptide preparations for the treatment of lung damage, asthma, anaphylaxis, angioedema, systemic syndromes of vascular permeability and nasal congestion - Google Patents

Peptide preparations for the treatment of lung damage, asthma, anaphylaxis, angioedema, systemic syndromes of vascular permeability and nasal congestion

Info

Publication number
IL229771B
IL229771B IL229771A IL22977113A IL229771B IL 229771 B IL229771 B IL 229771B IL 229771 A IL229771 A IL 229771A IL 22977113 A IL22977113 A IL 22977113A IL 229771 B IL229771 B IL 229771B
Authority
IL
Israel
Prior art keywords
angioedema
anaphylaxis
asthma
lung injury
vascular permeability
Prior art date
Application number
IL229771A
Other languages
English (en)
Hebrew (he)
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of IL229771B publication Critical patent/IL229771B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/033Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
IL229771A 2011-06-13 2013-12-03 Peptide preparations for the treatment of lung damage, asthma, anaphylaxis, angioedema, systemic syndromes of vascular permeability and nasal congestion IL229771B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161496409P 2011-06-13 2011-06-13
PCT/US2012/042118 WO2012174028A2 (en) 2011-06-13 2012-06-13 Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion

Publications (1)

Publication Number Publication Date
IL229771B true IL229771B (en) 2019-07-31

Family

ID=47357694

Family Applications (1)

Application Number Title Priority Date Filing Date
IL229771A IL229771B (en) 2011-06-13 2013-12-03 Peptide preparations for the treatment of lung damage, asthma, anaphylaxis, angioedema, systemic syndromes of vascular permeability and nasal congestion

Country Status (15)

Country Link
US (2) US9248198B2 (pt)
EP (1) EP2717897B1 (pt)
JP (1) JP6042425B2 (pt)
KR (1) KR102042015B1 (pt)
CN (2) CN106188232B (pt)
AU (1) AU2012271781C1 (pt)
BR (1) BR112013032108B1 (pt)
CA (1) CA2838662C (pt)
DK (1) DK2717897T3 (pt)
ES (1) ES2633343T3 (pt)
IL (1) IL229771B (pt)
MX (1) MX349146B (pt)
PL (1) PL2717897T3 (pt)
WO (1) WO2012174028A2 (pt)
ZA (1) ZA201309161B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102042015B1 (ko) * 2011-06-13 2019-11-07 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 폐 손상, 천식, 과민증, 혈관 부종, 전신 혈관 투과성 증후군 및 비충혈을 치료하는 펩티드 조성물과 이들로 이러한 질환을 치료하는 방법
SG11201706799YA (en) * 2015-03-02 2017-09-28 Univ Illinois Peptides for inhibiting angiogenesis
CN110128506B (zh) * 2019-05-22 2021-03-30 中国药科大学 一种寡肽及其应用
CN110664990B (zh) * 2019-11-07 2021-03-16 江南大学 一种trpc1肽类分子在制备治疗病毒感染引起的炎症的药物中的应用
WO2021211784A2 (en) * 2020-04-15 2021-10-21 Cohbar, Inc. Method of treating coronavirus infections

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US6093740A (en) * 1997-04-30 2000-07-25 Eli Lilly And Company Therapeutic treatment for skin disorders
GB9718609D0 (en) 1997-09-02 1997-11-05 Imp College Innovations Ltd Fusion protein
CA2545062A1 (en) 2003-11-06 2005-05-26 Research Development Foundation Selective inhibitors of nuclear factor-kb activation and uses thereof
JP4772690B2 (ja) * 2003-12-03 2011-09-14 ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド チューブリン阻害剤
EP1996013A4 (en) * 2005-09-21 2010-03-10 Dask Technologies Llc METHODS AND COMPOSITIONS FOR FUNCTIONALITY OF ORGANS AND TISSUES
KR101399175B1 (ko) * 2006-07-21 2014-06-19 푼다싸웅 지 앙빠루 아 뻬스끼자 두 에스따두 지 싸웅 파울루 - 에피아뻬에에씨뻬 항염증성 및 항알레르기성 시클릭 펩티드
US7585865B2 (en) * 2006-07-21 2009-09-08 The Penn State Research Foundation Protein kinase C zeta inhibition to treat vascular permeability
JP5542064B2 (ja) * 2008-01-22 2014-07-09 アライム ファーマシューティカルズ,インコーポレーテッド 組織の損傷に関連した疾患及び障害を予防及び治療する、組織保護ペプチド及びペプチド類似体
FR2940032B1 (fr) 2008-12-23 2013-08-09 Seb Sa Panier de cuisson d'aliments et systeme de cuisson correspondant
IT1392567B1 (it) * 2008-12-24 2012-03-09 Bioindustry Park Del Canavese S P A Uso di un peptide derivato da er-alfa per il ripristino della sensibilita' a composti antiestrogenici in cellule di tumore mammario
US20100190691A1 (en) * 2009-01-27 2010-07-29 Trojan Technologies, Ltd Delivery of nucleic acids using cell-penetrating peptides
KR102042015B1 (ko) * 2011-06-13 2019-11-07 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 폐 손상, 천식, 과민증, 혈관 부종, 전신 혈관 투과성 증후군 및 비충혈을 치료하는 펩티드 조성물과 이들로 이러한 질환을 치료하는 방법

Also Published As

Publication number Publication date
AU2012271781A1 (en) 2014-01-09
JP2014518211A (ja) 2014-07-28
US9248198B2 (en) 2016-02-02
DK2717897T3 (en) 2017-07-17
CA2838662C (en) 2018-07-24
AU2012271781B2 (en) 2017-02-16
EP2717897A2 (en) 2014-04-16
KR102042015B1 (ko) 2019-11-07
PL2717897T3 (pl) 2017-09-29
JP6042425B2 (ja) 2016-12-14
EP2717897B1 (en) 2017-04-19
ES2633343T3 (es) 2017-09-20
BR112013032108A2 (pt) 2016-11-22
WO2012174028A2 (en) 2012-12-20
MX349146B (es) 2017-07-14
KR20140056185A (ko) 2014-05-09
ZA201309161B (en) 2015-03-25
US8912139B2 (en) 2014-12-16
BR112013032108B1 (pt) 2021-10-26
WO2012174028A3 (en) 2013-02-21
CN103608026A (zh) 2014-02-26
CA2838662A1 (en) 2012-12-20
MX2013014650A (es) 2014-01-24
US20140155314A1 (en) 2014-06-05
EP2717897A4 (en) 2015-01-07
CN106188232A (zh) 2016-12-07
US20140213505A1 (en) 2014-07-31
AU2012271781C1 (en) 2017-09-21
CN106188232B (zh) 2020-01-07
CN103608026B (zh) 2016-08-24

Similar Documents

Publication Publication Date Title
HK1224152A1 (zh) 吸烟製品及其用於產生吸入物質的用途
PL3593654T3 (pl) Artykuły do palenia oraz inne doprowadzające przepływ artykuły
EP2720632B8 (en) Devices for treating nasal airways
PL2719416T3 (pl) Inhalator aerozolowy
ZA201400792B (en) Novel piperidono-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
HK1211523A1 (en) Ventilator aerosol delivery system
IL232226B (en) Albumin-binding antibodies and their binding fragments
AP2012006639A0 (en) Nasal aerosol delivery system
IL229771B (en) Peptide preparations for the treatment of lung damage, asthma, anaphylaxis, angioedema, systemic syndromes of vascular permeability and nasal congestion
ZA201109492B (en) Compositions comprising finafloxacin and methods for treating ophthalmic,otic,or nasal infections
EP2720742A4 (en) INHALATION MEDICAMENT DEVICES, VALVES AND COMPONENTS THEREFOR
EP2500054A4 (en) GAS FOG INHALER
EP2687204A4 (en) VECTOR FOR PULMONARY ADMINISTRATION, INDUCTION AGENT, AND USES
EP2753363A4 (en) MG53 COMPOSITIONS AND METHOD FOR THE TREATMENT AND PREVENTION OF RESPIRATORY INFLUENZES
GB2505810B (en) Nasal aroma breathing pipe
EP2594283A4 (de) Aerosolpräparat auf aprotininbasis zur behandlung von virusinfektionen der atemwege
HK1169334A1 (en) Inhaled combination product for asthma
AU339359S (en) Respiratory mask and/or components thereof
HK1182033A1 (zh) 定量吸入器致動器、定量吸入器
GB201006353D0 (en) Nasal inhaler
WO2013135395A8 (en) Composition comprising arabinogalactan and polyphenols from larch trees
GB0705339D0 (en) Asthma inhaler
GB0910212D0 (en) Safety asthma inhaler
GB201008244D0 (en) Instahaler, low-pressure triggered respirator or inhaler
FI20110021A0 (fi) Kaasutoiminen savukeperusteinen nikotiini- ja tupakka-aromi-inhalaattori

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed